Botulinum toxin type A for treating chronic low back pain: A double blinded randomized control study.

Area of Science:

• Orthopedics
• Pain Management
• Neurology

Background:

• Low back pain (LBP) is a common condition managed by orthopedic surgeons.
• Paraspinal muscle stiffness contributes to LBP.
• Botulinum toxin type A (BoNT-A) may alleviate LBP by relaxing muscles, but limited RCTs support its use for LBP.

Purpose of the Study:

• To evaluate the safety and efficacy of BoNT-A for chronic low back pain (CLBP).
• To assess BoNT-A's impact on pain reduction and functional outcomes in CLBP patients.

Main Methods:

• A randomized clinical trial (RCT) involving adults aged 18-60 with mechanical LBP for at least six months.
• Participants received either 200 Ipsen Units of BoNT-A or a placebo.
• Pain (VAS) and disability (ODI) were assessed over a 2-month follow-up.

Main Results:

• A clinically significant pain reduction (50%) was noted in 36 out of 40 participants.
• Both groups showed statistically significant decreases in VAS and ODI scores post-treatment.
• However, only ODI score changes were statistically significant between groups (P=0.012), not VAS scores (P=0.45).

Conclusions:

• BoNT-A did not demonstrate a short-term advantage over placebo in improving pain or disability scores for CLBP patients.
• The study suggests BoNT-A is not a superior short-term treatment for CLBP compared to placebo.